Gelesis Holdings, Inc. (GLS)

NYSE: GLS · IEX Real-Time Price · USD
0.384
-0.026 (-6.32%)
Nov 25, 2022 1:00 PM EDT - Market closed
-6.32%
Market Cap 32.46M
Revenue (ttm) 26.03M
Net Income (ttm) -44.83M
Shares Out 72.77M
EPS (ttm) -10.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 115,658
Open 0.409
Previous Close 0.41
Day's Range 0.353 - 0.449
52-Week Range 0.24 - 12.23
Beta 0.85
Analysts Sell
Price Target 1.17 (+204.8%)
Earnings Date Nov 14, 2022

About GLS

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and ... [Read more]

Industry Biotechnology
Founded 2006
CEO Yishai Zohar
Employees 101
Stock Exchange NYSE
Ticker Symbol GLS
Full Company Profile

Financial Performance

In 2021, GLS's revenue was $11.19 million, a decrease of -47.84% compared to the previous year's $21.44 million. Losses were -$93.35 million, 260.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for GLS stock is "Sell." The 12-month stock price forecast is 1.17, which is an increase of 204.85% from the latest price.

Price Target
$1.17
(204.85% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Gelesis Reports Upcoming Participation in Wolfe Research's Annual Consumer Growth Conference

BOSTON--( BUSINESS WIRE )--Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today announced that its Chief Operating & Commercial Officer, Dav...

5 days ago - Business Wire

Gelesis Receives Notice of NYSE Market Capitalization Listing Rule Non-Compliance

BOSTON--( BUSINESS WIRE )--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) today noted that on November 16, 2022, the Company received a notification letter (the “Notice”) from the New Yo...

1 week ago - Business Wire

Gelesis Reports Third Quarter 2022 Results

BOSTON--( BUSINESS WIRE )--Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today reported financial results for the third quarter of 2022. Pl...

1 week ago - Business Wire

Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022

BOSTON--(BUSINESS WIRE)--Gelesis Holdings, Inc. (NYSE:GLS) (“Gelesis” or the “Company”), the maker of Plenity® for weight management, today announced that the Company will report financial results for t...

2 weeks ago - Business Wire

Gelesis Receives Notice of NYSE Trading Share Price Listing Rule Non-Compliance

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) today noted that the Company received a notification letter from the New York Stock Exchange (the “NYSE”) advising...

3 weeks ago - Business Wire

Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel G...

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released new data at Obesity Week in San Diego.

3 weeks ago - Business Wire

Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis' Oral Hydrogel Treatment GS200 at Obesity Week

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today announced Dr. Frank Greenway will give an oral presentation at O...

3 weeks ago - Business Wire

Gelesis to Participate in the Jefferies Virtual Fitness & Wellness Summit

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Office...

2 months ago - Business Wire

Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis O...

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released a poster presentation at the International Congress of ...

3 months ago - Business Wire

Gelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ET

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today announced that the Company is participating in a fireside chat w...

3 months ago - Business Wire

Gelesis Reports Second Quarter 2022 Results

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today reported financial results for the second quarter of 2022. “We are seeing both consumers and clinicians em...

3 months ago - Business Wire

Gelesis to Report Second Quarter 2022 Financial Results on August 15, 2022

BOSTON--(BUSINESS WIRE)--Gelesis Holdings, Inc. (NYSE:GLS) (“Gelesis” or the “Company”), the maker of Plenity® for weight management, today announced that the Company will report financial results for t...

3 months ago - Business Wire

Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity t...

BOSTON--(BUSINESS WIRE)--Gelesis announced today that Ro, a leading and rapidly growing U.S. direct-to-patient healthcare company, has placed a $15 million pre-paid order for the company's commercial pr...

5 months ago - Business Wire

Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1...

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, presented new findings about the role of language in obesity and diabetes scientific literature at the American ...

5 months ago - Business Wire

Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects ...

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, presented new preclinical data showing weight loss and additional metabolic benefits in mice receiving a microbi...

5 months ago - Business Wire

Gelesis to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer, a...

6 months ago - Business Wire

Gelesis Reports First Quarter 2022 Results

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today reported financial results for the first quarter of 2022. “We saw all-time highs of people seeking and sta...

6 months ago - Business Wire

Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity® for weight management, today announced that the Company will report financial results for the First Quarter ended March 31, 2022, on M...

6 months ago - Business Wire

Clinical Data Presented at the European Congress on Obesity 2022 Demonstrates Weight Loss With GS200 in Adults With P...

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), a consumer-focused biotherapeutics company and the maker of Plenity®, today presented results from the LIGHT-UP clinical trial for adults with overweight or...

6 months ago - Business Wire

Gelesis' Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansi...

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), a consumer-focused biotherapeutics company and the maker of Plenity®, released today a poster presentation at the World of Microbiome annual meeting in Vien...

6 months ago - Business Wire

Gelesis® Reports Fiscal Year 2021 Results and Fiscal Year 2022 Financial Outlook

BOSTON--(BUSINESS WIRE)---- $GLS #earnings--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today reported financial results for its fiscal year ended December 31, 2021. Yishai Zohar, F...

8 months ago - Business Wire

Gelesis to Report Full Year 2021 Financial Results on March 24, 2022

BOSTON--(BUSINESS WIRE)---- $GLS #earnings--Gelesis (NYSE: GLS), the maker of Plenity® for weight management, today announced that the Company will report financial results for fiscal year 2021 on March...

8 months ago - Business Wire

Gelesis® Releases Preliminary National Launch Results for Plenity®: Record-Breaking Levels of Prescriptions and Onlin...

BOSTON--(BUSINESS WIRE)---- $GLS--Gelesis (NYSE: GLS), the maker of Plenity, announced preliminary results from its broad awareness media campaign that debuted January 31, 2022. Within the first three w...

8 months ago - Business Wire

Plenity® National Media Campaign Kicking Off Today Challenges Restrictive Dieting Norms

BOSTON--(BUSINESS WIRE)---- $GLS--Who said losing weight has to be miserable? The debut “Who Said?” campaign from Plenity, launching today across the US, challenges many long-held cultural and societal ...

9 months ago - Business Wire

Gelesis, Maker Of Weight Loss Pill, Concludes SPAC Deal; Trading Kickstarts Today

PureTech Health plc (NASDAQ: PRTC) founded entity Gelesis Inc, maker of weight management aid, has completed its business combination with Capstar Special Purpose Acquisition Corp (NYSE: CPSR).  The pub...

10 months ago - Benzinga